![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, June 27, 2019 11:30:49 AM
All should realize Steve Demattos has a very close tie with Ronald Bradley Demattos so why has the new BOD NOT done their fiduciary duties and look into everything as now they are officially going to be placed on warning that some are trying awfully hard to conceal the true value of the IP surrounding PS Targeting / biomarkers etc
Let us review and as you weave thru the puzzle pieces, Merck has an objective and it is to pick up all of PS Targeting IP value driver biomarkers via others help and that would be illegal to manipulate stock prices as John Springs Stafford is well aware
________
David M Holtzman on patents with Cheryl Leyns who is poached by Merck and yes, more to come
The new BODs have fiduciary duties to extract all values ...all avenues ...to maximize shareholder value and someone wants to buy out a CDMO because some want to HIDE the IP asset valuations behind biomarkers etc
Don't let it happen and all send in to IR that this is not acceptable
A bonus for you all: Heather Preston and David Preston ...some of it mentioned before but ties from Pivotal Bioventures to Advent International
https://www.adventinternational.com/bioduro-partners-with-advent-international/
First things first though.... the FBI investigations looked long into the DeMattos ...I certainly hope they are smarter than I
_________
No public announcement from the new BODs in regards to Steve Demattos departure of Pergrine Pharmaceuticals ? No excuse because the new BODs CAN NOT use the excuse that what happened in the past has no bearing now because it certainly matters. It matters because who knows what was concealed in the depositions or what trade secrets were use with Steve Demattos over at Xencor now ....the same Xencor and here John Stafford has left their BOD but buying up alot of Xencor stock this past year.....which all coincides with Stafford / Steve White with Ronin Hedge Group as it seems they are trying to conceal the true value of PS Targeting IP ...
Steve Demattos listed as contact for Xencor trial
Contact: Steve DeMattos, BS 858-480-3892 sdemattos@xencor.com
https://clinicaltrials.gov/ct2/show/NCT02725515
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138048080
_______
Ronald Bradley Demattos
age 49
Get Full Report on Ronald
ADDRESS HISTORY
Zionsville, IN
Fishers, IN
Noblesville, IN
Indianapolis, IN
Saint Louis, MO
Centereach, NY
Stony Brook, NY
East Setauket, NY
Port Jefferson Station, NY
Northville, MI
RELATIVES
Matthew Demattos
Yvonne Demattos
Abel Demattos
Steven Demattos
Alyssa Demattos
David Demattos
Shong Demattos
_________
Ronald DeMattos
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company
Indianapolis, Indiana Area
Pharmaceuticals500+
Summary
Ronald B. DeMattos, Ph.D. is currently a Chief Scientific Officer for Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company. Dr. DeMattos received his doctorate in molecular and cellular biochemistry from State University of New York â?? Stony Brook in 1998. During his post-doctoral fellowship at Washington University School of Medicine (laboratory of David M. Holtzman), Dr. DeMattos performed the foundational studies that led to the development of the peripheral sink hypothesis for Alzheimerâ??s immunotherapy as well as the original antibody studies that would eventually lead to Eli Lillyâ??s Phase III drug candidate Solanezumab. Dr. DeMattos was recruited to Eli Lilly as a Research Scientist in 2002 and he has subsequently been promoted six times. He has led multiple successful programs targeting Alzheimerâ??s disease (compounds in Phase-1 and Phase-3) and he has played a major role in expanding the immunotherapy platform. Under Dr. DeMattosâ??s leadership, his team has provided many important deliverables for the Neuroscience division wherein they have developed scientific rationale, identified biomolecules, developed and performed innovative SAR, delivered key proof of concept data, and championed several large molecules through all phases of development (one of which is currently in Phase III clinical trials). Dr. DeMattos has developed the scientific rationale and corresponding assays to support clinical biomarker studies (7 different validated biomarker assays have been utilized in the clinic). Dr. DeMattos has played a key role in developing Lillyâ??s Alzheimerâ??s strategy and he has been a key resource for numerous functions beyond discovery. Dr. DeMattos currently leads the Indianapolis Neuroscience site comprised of talented scientists and staff whose mission is to develop novel first-in class therapies for Neuroscience indications, with significant emphasis on neurodegeneration and Alzheimerâ??s disease.
Specialties: Alzheimer's disease, drug development, clinical biomarker development, preclinical to clinical translational studies, in vivo pharmacology, lipoprotein biology, immunotherapy, pharmacology and biochemistry,
Experience
Image for Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Eli Lilly and Company
June 2002 â?? Present 17 years 1 month
Image for Instructer in Neurology
Instructer in Neurology
Washington University School of Medicine
June 1999 â?? June 2002 3 years 1 month
People also viewed
J. Carmel Egan
Associate Dean for Research Affairs , IU School of Medicine and COO Indiana CTSI
Henry Bryant
Distinguished Research Fellow at Lilly Research Laboratories
Janelle Sabo
Global Head, Product Delivery at Eli Lilly and Company
Bradley Miller MD, PhD
Senior Managing Director in Neuroscience
Charles Mitch
Eli Lilly (retired)
Jeffrey Witkin
Chief Executive Officer at Witkin Consulting Group
Patrick May
President at ADvantage Neuroscience Consulting LLC
Juan Jose Carrillo
Director at Eli Lilly and Company
Francis Willard
Research Scientist at LRL
Larry Blaszczak
Independent Pharmaceutical Consultant, Indianapolis Indiana Area.
_______
Top co-authors (50)
David M Holtzman
Washington University in St. Louis
Steven M Paul
Kelly Bales
Roche Pharma Research & Early Development
Margaret M. Racke
Robert A Dean
Eli Lilly
Affiliations
Eli Lilly and Company
United States Naval Research Laboratory
Philipps University of Marburg
University of Illinois at Chicago
Indianapolis Zoo
University of British Columbia - Vancouver
Department
Department of Pathology and Laboratory Medicine
Columbia University
Eli Lilly
Department
Lilly Research Laboratories
Duke University
Department
Department of Medicine
Indiana University-Purdue University Indianapolis
Department
Department of Psychiatry
Carnegie Mellon University
Department
Department of Chemistry
Washington University in St. Louis
Department
Department of Neurology
University of California, San Diego
State University of New York
Hackensack University Medical Center
Massachusetts Institute of Technology
Department
Department of Biology
https://www.google.com/amp/s/www.researchgate.net/scientific-contributions/39737839_Ronald_B_DeMattos/amp
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM